The finding that dual BRAF/MEK inhibition prevents the onset of resistance in our in vitro melanoma models suggests that MEK inhibitors may be of use in managing resistance to BRAF inhibitors and may delay or even prevent the onset of resistance in some cases. The gene discussed is MAP2K7; the disease is melanoma.